A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With an Open-Label Extension to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy
Latest Information Update: 08 May 2024
At a glance
- Drugs Ifetroban (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Acronyms DMD; FIGHT DMD
- Sponsors Cumberland Pharmaceuticals
- 05 Mar 2024 According to a Cumberland Pharmaceuticals media release, the Company has completed enrollment in the younger age group of patients and now is working to finish enrollment in the older patient group with DMD.
- 07 Nov 2023 According to a Cumberland Pharmaceuticals media release, trial is evaluating 24 subjects with early-stage cardiomyopathy and 24 subjects with advanced-stage heart disease across 10 U.S. centers that specialize in DMD cardiomyopathy.
- 08 Aug 2023 According to a Cumberland Pharmaceuticals media release, interim results from this study were presented at the 29th annual Parent Project Muscular Dystrophy Conference in Dallas.